ロード中...
In silico structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors
The high mortality rate from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in humans and the lack of effective therapeutic regime for its treatment necessitates the identification of new antivirals. SARS-CoV-2 relies on non-structural proteins such as Nsp13 helicase and...
保存先:
| 出版年: | Gene Rep |
|---|---|
| 第一著者: | |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier Inc.
2020
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7452913/ https://ncbi.nlm.nih.gov/pubmed/32875166 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.genrep.2020.100860 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|